Morningstar
•
May 27, 2026
Insulet Corporation: Insulet: Ongoing Challenges With Quality Add Near-Term Turbulence
Summary
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Tandem Diabetes Care, Inc.
May 28, 2026
•
TNDM
The Argus Sustainable Growth Theme Model Portfolio
May 28, 2026
•
TT, DE, GOOGL, NDAQ, AAPL, AVGO, JPM, ADI, MRK, JNJ, TXN, TFC, MSFT, GLW, MA, LLY, TRV, SPGI, GE, NVDA, NOC, KO, KMI, AEP, GS, ECL, TMUS, AMZN, ETN, WMT
TRUP: What does Argus have to say about TRUP?
May 27, 2026
•
TRUP, DXCM
TNDM: Raising target price to $13.00
May 27, 2026
•
TNDM
MASI: What does Argus have to say about MASI?
May 27, 2026
•
MASI
Analyst Profile
Debbie S. Wang
Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.
